Entrada Therapeutics, Inc. (TRDA)
NGM – Real Time Price. Currency in USD
7.23
+0.19 (2.70%)
Market open: Aug 12, 2026, 11:50 AM EDT
7.04
0.00 (0.00%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Find any stock by ticker or company name

NGM – Real Time Price. Currency in USD
7.23
+0.19 (2.70%)
Market open: Aug 12, 2026, 11:50 AM EDT
7.04
0.00 (0.00%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
No Data
There are no news for this stock.
Company's cash reserves $99.3M significantly exceed its total debt $48.5M, ensuring strong financial flexibility
Total current assets $232.7M exceed Total current liabilities $21.4M, highlighting excellent liquidity
Debt-to-equity ratio (0.2) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$32.5M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 10.89 | 6.05 | 10 | |
| Quick ratio | 10.89 | 5.63 | 10 | |
| Debt to Equity | 0.21 | 0.30 | 9.0 | |
| Debt to Assets | 0.16 | 1.04 | 8.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.6 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | 129M | 211M | 25M | 5M |
| Gross Profit | -2M | 126M | 207M | 21M | 995K |
| Operating Income | -97M | -3M | 47M | -156M | -177M |
| Net Income | -95M | -7M | 66M | -144M | -166M |
| EBITDA | -95M | -321K | 51M | -152M | -173M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 139.3 | 8.96 | 8.0 |
| Next quarter | 381.36 | -3.86 | 5.5 |
| Current year | -47.98 | -12.97 | 1.0 |
| Next year | 96.25 | 10.78 | 8.5 |
| Weighted average score | 5.8 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 2.63 | -7.66 | -6.31 | 22.2 | 4.0 |
| Y/Y | -53.94 | 0.79 | 2.88 | -9.09 | 2.0 |
| 3y average | 324.82 | 285.2 | 242.28 | -28.06 | 7.8 |
| 5y average | 594.49 | 135.56 | 197.46 | -51.45 | 7.8 |
| Weighted average score | 5.4 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |